Loading provider…
- Featuresarrow_drop_down
- Solutionsarrow_drop_down
Loading provider…
Your Medical Sales Assistants that help you easily find, convert and close your ideal providersNeurology Physician in Cincinnati, OH
NPI: 1114190014Primary Practice Location
UNIVERSITY OF CINCINNATI MEDICAL CENTER, LLC
3188 Bellevue Ave, Cincinnati, OH
Primary Employer
University of Cincinnati Physicians Company, LLC
ucphysicians.com
HQ Phone
Get M.D. Aram's Phone NumberMobile
Get M.D. Aram's MobileLooking to connect with more Physicians?
Dmand AI gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Get Started for Freearrow_outwardOH State Medical License
| # | Procedure Code (CPT®/HCPCS II) | Procedure Patients | Procedure Volume |
|---|---|---|---|
| 1 | 99215Established patient office or other outpatient, visit typically 40 minutes | 66 | 77 |
| 2 | 99214Established patient office or other outpatient visit, 30-39 minutes | 38 | 42 |
| 3 | 99213Established patient office or other outpatient visit, typically 15 minutes | 16 | 17 |
Inebilizumab for treatment of neuromyelitis optica spectrum disorder.
Authors: J Tullman, Mark, Zabeti, Aram, Vuocolo, Scott, Dinh, Quinn
Journal: Neurodegener Dis Manag
Publication Date: 2021-09-06
Authors: Mousavi, Pegah, Emadzadeh, Maryam, Karimikhoshnoudian, Bahar, Sahraian, Mohammad Ali, Ghaffari, Mehran, Shaygannejad, Vahid, Payere, Maryam, Baghaei, Ava, Zabeti, Aram, Nahayati, Mohammadali
Journal: Naunyn Schmiedebergs Arch Pharmacol
Publication Date: 2025-06-11
Long-term efficacy and safety of inebilizumab in neuromyelitis optica spectrum disorder: Analysis of aquaporin-4-immunoglobulin G-seropositive participants taking inebilizumab for ⩾4 years in the N-MOmentum trial.
Authors: Mary Rensel
Publication Date: 2021-10-01
Lead Sponsor: The Cleveland Clinic
Collaborators: University of Nottingham
Intervention / Treatment: DRUG: Early Highly Effective Therapies Group, DRUG: Escalation Therapies Group
